![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novigenix Buys Colorectal Cancer Test
Novigenix Buys Colorectal Cancer Test
![](https://www.fdanews.com/ext/resources/test/Drug-Images/handshake.jpg?t=1433878528&width=230)
Swiss molecular diagnostics firm Novigenix announced Thursday that it purchased Diagnoplex’s Colox colorectal cancer test for an undisclosed sum.
Colox detects colorectal cancer from a drop of blood by checking the gene expression signature of 29 genes in peripheral blood mononuclear cells. The test is expected to allow earlier diagnosis and treatment of the disease — and thereby cut mortality rates — by increasing compliance with routine screening, Lausanne, Switzerland-based Novigenix said.
The product was evaluated in a clinical trial at Centre Hospitalier Universitaire Vaudois in Lausanne and is CE-marked for sale in Europe. Novigenix plans to initially make Colox available within Switzerland and then roll it out across Europe via partnerships. — Elizabeth Orr
Upcoming Events
-
21Oct